Maccabi Fund
VC Fund
Maccabi Fund is an investment fund.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 45%
Last updated:
For AI agents: llms.txt
Industries Maccabi Fund invests in
Health CareArtificial IntelligenceMedical DeviceSoftwareHealth Diagnostics
Stages Maccabi Fund invests in
SeedSeries AGrantPre-SeedFunding Round
Countries Maccabi Fund invests in
IsraelUnited States
Round sizes
Seed $1.5M–$6.7MSeries A $1.5M–$15M
Round size
- Seed
- $1.5M–$6.7M
- Series A
- $1.5M–$15M
Investment Focus
Industry
- Health Care 5 (45%)
- Artificial Intelligence 4 (36%)
- Medical Device 3 (27%)
- Software 2 (18%)
- Health Diagnostics 2 (18%)
Stage
- Seed 4 (36%)
- Series A 2 (18%)
- Grant 1 (9%)
- Pre-Seed 1 (9%)
- Funding Round 1 (9%)
Country
- Israel 4 (36%)
- United States 2 (18%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Rhino Federated Computing solves one of the biggest challenges in AI: seamlessly connecting siloed data through federated computing. The Rhino Federated Computing Platform (RhinoFCP) serves as the ‘data collaboration tech stack’, extending from providing computing resources to data preparation & discoverability, to model development &monitoring — all in a secure, privacy-preserving environment. To do this, Rhino FCP offers flexible architecture (multi-cloud and on-prem hardware), end-to-end data management workflows (multimodal data, schema definition, harmonization, and visualization), privacy enhancing technologies (e.g., differential privacy), and allows for the secure deployment of custom code & 3rd party applications via persistent data pipelines. Rhino is trusted by >60 leading organizations worldwide — including 14 of 20 of Newsweek’s ‘Best Smart Hospitals’ and top 20 global biopharma companies — and is leveraging this foundation for financial services, ecommerce, and beyond. The company is headquartered in Boston, with an R&D center in Tel Aviv. | $15M / Series A / May 22, 2025 | ||
| AccuLine is a digital healthcare company, which was founded with the vision to saves the lives of millions of people worldwide. AccuLine is developing CORA—a smart, accurate, and easy to use exam for the early detection of coronary artery disease. The clinically validated CORA evaluates a patient's risk of having coronary artery diseasethrough advanced analysis and detection of two newly discovered biomarkers in the heart’s electrical activity. CORA’s early detection will assist in the prevention of sudden cardiac deaths, while lowering costs of cardiovascular related illness. | $3.5M / Seed / May 01, 2024 | ||
| It's About me (IAM) has developed a passive sensor mounted to the rim of the toilet that performs urinalysis every time the end-user urinates. The information is uploaded to a robust data science platform to track existing and progressing conditions. Real-time, actionable notifications will be sent to the end user for proactive medical ornutritional care. Ongoing biomarker tracking for hydration, Alcohol, Pregnancy, Ovulation, Keytones, etc. is used to develop a comprehensive personal user profile.The technology will also be used for pharma and CRO companies to track the usage of drugs. While drug compliance issues plague health care systems around the world, I AM's technology will provide a reliable and continuous solution for tracking when and how people take their medicine or clinical trial drug.Nonindustrial nations will now have home access to urine lab services. | $1M / Grant / Jan 09, 2023 | ||
| It's About me (IAM) has developed a passive sensor mounted to the rim of the toilet that performs urinalysis every time the end-user urinates. The information is uploaded to a robust data science platform to track existing and progressing conditions. Real-time, actionable notifications will be sent to the end user for proactive medical ornutritional care. Ongoing biomarker tracking for hydration, Alcohol, Pregnancy, Ovulation, Keytones, etc. is used to develop a comprehensive personal user profile.The technology will also be used for pharma and CRO companies to track the usage of drugs. While drug compliance issues plague health care systems around the world, I AM's technology will provide a reliable and continuous solution for tracking when and how people take their medicine or clinical trial drug.Nonindustrial nations will now have home access to urine lab services. | $2M / Seed / Jan 01, 2023 | ||
| Our mission is to empower medical AI researchers and developers by unlocking the world's disparate data sets using Federated Learning. | $6.7M / Aug 27, 2022 | ||
| Rhino Federated Computing solves one of the biggest challenges in AI: seamlessly connecting siloed data through federated computing. The Rhino Federated Computing Platform (RhinoFCP) serves as the ‘data collaboration tech stack’, extending from providing computing resources to data preparation & discoverability, to model development &monitoring — all in a secure, privacy-preserving environment. To do this, Rhino FCP offers flexible architecture (multi-cloud and on-prem hardware), end-to-end data management workflows (multimodal data, schema definition, harmonization, and visualization), privacy enhancing technologies (e.g., differential privacy), and allows for the secure deployment of custom code & 3rd party applications via persistent data pipelines. Rhino is trusted by >60 leading organizations worldwide — including 14 of 20 of Newsweek’s ‘Best Smart Hospitals’ and top 20 global biopharma companies — and is leveraging this foundation for financial services, ecommerce, and beyond. The company is headquartered in Boston, with an R&D center in Tel Aviv. | $6.7M / Seed / Aug 27, 2022 | ||
| It's About me (IAM) has developed a passive sensor mounted to the rim of the toilet that performs urinalysis every time the end-user urinates. The information is uploaded to a robust data science platform to track existing and progressing conditions. Real-time, actionable notifications will be sent to the end user for proactive medical ornutritional care. Ongoing biomarker tracking for hydration, Alcohol, Pregnancy, Ovulation, Keytones, etc. is used to develop a comprehensive personal user profile.The technology will also be used for pharma and CRO companies to track the usage of drugs. While drug compliance issues plague health care systems around the world, I AM's technology will provide a reliable and continuous solution for tracking when and how people take their medicine or clinical trial drug.Nonindustrial nations will now have home access to urine lab services. | $1.5M / Seed / May 25, 2022 | ||
| AccuLine is a digital healthcare company, which was founded with the vision to saves the lives of millions of people worldwide. AccuLine is developing CORA—a smart, accurate, and easy to use exam for the early detection of coronary artery disease. The clinically validated CORA evaluates a patient's risk of having coronary artery diseasethrough advanced analysis and detection of two newly discovered biomarkers in the heart’s electrical activity. CORA’s early detection will assist in the prevention of sudden cardiac deaths, while lowering costs of cardiovascular related illness. | $400K / Pre-Seed / Mar 01, 2022 | ||
| DermaDetect was co-founded a year ago by four experienced entrepreneurs and is clinically led by Prof. Arieh Ingber, former head of department of dermatology in Hadassa Medical Center in Israel, a world-renowned dermatologist.We've developed a diagnostics & treatment tool/app (Apple, Android, Web), which enables healthcareprofessionals and patients to self-triage & manage skin disorders. The underlying technology is based on the combination of two approaches: dermatological rule base inference & image analysis using machine learning.We’re in a progress of a pilot-study to validate the effectiveness of our technology within the Israeli Health system, which is world’s best sandbox for such a study.Funded by two angel investors, eHealth Ventures [and their partners: Maccabi Healthcare Services in Israel (second biggest HMO in Israel), the Cleveland Clinic (the second largest healthcare provider in the US), Amgen], and supported by the Israel Innovation Authority. | $2.2M / Seed / Jan 01, 2022 | ||
| It's About me (IAM) has developed a passive sensor mounted to the rim of the toilet that performs urinalysis every time the end-user urinates. The information is uploaded to a robust data science platform to track existing and progressing conditions. Real-time, actionable notifications will be sent to the end user for proactive medical ornutritional care. Ongoing biomarker tracking for hydration, Alcohol, Pregnancy, Ovulation, Keytones, etc. is used to develop a comprehensive personal user profile.The technology will also be used for pharma and CRO companies to track the usage of drugs. While drug compliance issues plague health care systems around the world, I AM's technology will provide a reliable and continuous solution for tracking when and how people take their medicine or clinical trial drug.Nonindustrial nations will now have home access to urine lab services. | $4M / Seed / Aug 24, 2021 | ||
| See all 11 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
SaaS Investors
117,441 investors
Software Investors
57,331 investors
Health Care Investors
48,627 investors
Artificial intelligence Investors
45,634 investors
Medical Device Investors
12,432 investors
SaaS VC Funds
71,923 investors
Software VC Funds
36,593 investors
Health Care VC Funds
36,465 investors
Artificial intelligence VC Funds
30,673 investors
FAQ
What does Maccabi Fund invest in?
Maccabi Fund invests primarily in Health Care, Artificial Intelligence and Medical Device startups, most often at Seed and Series A stage. Most of the 11 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Maccabi Fund's check size?
Maccabi Fund typically joins rounds of $1.5M–$6.7M at Seed and $1.5M–$15M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Maccabi Fund participates in.
When did Maccabi Fund last invest?
The most recent investment recorded for Maccabi Fund closed in May 2025. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
